Detalhe da pesquisa
1.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246328
2.
Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children.
Pediatr Blood Cancer
; 68(7): e29056, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844446
3.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
4.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
5.
Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.
Pediatr Blood Cancer
; 71(6): e30961, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556730
6.
Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States.
J Nucl Med
; 65(5): 746-752, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38514088
7.
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
J Nucl Med Technol
; 51(1): 22-25, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195446
8.
Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
J Nucl Med
; 63(9): 1326-1333, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34992153
9.
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.
Cancers (Basel)
; 14(8)2022 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454822
10.
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
J Nucl Med
; 63(2): 226-232, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34049987
11.
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
J Nucl Med
; 62(10): 1447-1456, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272322
12.
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
J Nucl Med
; 62(10): 1440-1446, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016732
13.
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.
J Nucl Med
; 61(6): 890-896, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924723
14.
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.
Eur Urol
; 78(2): 148-154, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32532512
15.
Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.
Mol Cancer Ther
; 18(5): 1012-1021, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30926632
16.
Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
J Nucl Med
; 64(9): 1361-1363, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591543
17.
Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Clin Nucl Med
; 42(11): 822-828, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832377
18.
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Clin Nucl Med
; 42(6): 436-443, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28263217
19.
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
J Nucl Med
; 47(3): 534-42, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16513624
20.
Radiosynthesis of clinical doses of 68Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68Ge/68Ga generators.
Nucl Med Biol
; 43(1): 19-26, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26702783